ScaleReady announces a G-Rex® Grant has been awarded to LIfT Biosciences
ScaleReady announces a G-Rex® Grant has been awarded to LIfT Biosciences |
[09-October-2024] |
ST. PAUL, Minn., Oct. 9, 2024 /PRNewswire/ -- ScaleReady™, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation (NASDAQ: TECH) and CellReady™, and LIfT BioSciences, ('LIfT' or 'the Company'), a rapidly emerging biotech company about to start clinical trials for its first-in-class allogeneic innate cell therapy, today announced that LIfT Biosciences has been awarded a $300,000 G-Rex® Grant to establish clinical manufacturing of its promising Neutrophil only Leukocyte Infusion Therapy (N-LIfT) platform. John Wilson, CEO of Wilson Wolf and co-inventor of G-Rex, said: "We're eager to use our expertise to quickly create a highly efficient and scalable G-Rex manufacturing platform that will allow LIfT Biosciences to assess the potential of N-LIfT to penetrate the solid tumor microenvironment, kill cancer cells, and simultaneously recruit the patient's endogenous immune system." Andrew Willis, Chief Development and Regulatory Officer at LIfT Biosciences, said: "Once infused, N-LIfT produces a new type of myeloid cell called an Immunomodulatory Alpha Neutrophil (IMAN) which is an enhanced neutrophil that is designed to overcome treatment resistance in solid tumours. IMANs can identify solid tumors irrespective of antigen and kill them both directly and indirectly via recruiting the patient's own cancer killing immune cells into the tumour site. We've selected G-Rex as our clinical manufacturing platform and associated expertise that comes with it to expedite our path to patient treatment." As part of the G-Rex Grant, LIfT will collaborate with ScaleReady to establish a fully closed and semi-automated G-Rex manufacturing process suitable for scale out to late stage clinicals and beyond. ScaleReady's G-Rex Grant Program is a $20M initiative to advance the state of cell and gene-modified cell therapy (CGT) development and manufacturing by awarding individual Grant Awards worth up to $300,000. G-Rex Grant Recipients also gain access to exclusive support from ScaleReady's growing consortium of G-Rex Grant Partners who bring best-in-class tools and technologies as well as unparalleled knowledge and expertise in the areas of cGMP manufacturing, quality and regulatory affairs, CGT business operations, and more. About LIfT BioSciences The company is preparing initiatives with a range of pharmaceutical license partners to develop a portfolio of engineered CAR IMAN cell therapies to destroy a range of solid tumours. See www.LIfTbiosciences.com Contact: ICR Consilium About ScaleReady The G-Rex manufacturing platform is currently used by a rapidly growing list of over 800 organizations and is producing drug products for approximately 50% of CGT clinical trials as well as 5 commercially approved CGT drugs. CGT entities relying on the breadth and scope of ScaleReady's expertise can expect to save years of time and millions of dollars on the path to CGT commercialization. For more information about the ScaleReady G-Rex® Grant Program, please contact info@scaleready.com. About Wilson Wolf Manufacturing Wilson Wolf's mission is to create hope for cancer patients, one G-Rex® device at a time. About Bio-Techne Corporation Contact: David Clair, Vice President, Investor Relations & Corporate Development About CellReady LLC
View original content to download multimedia:https://www.prnewswire.com/news-releases/scaleready-announces-a-g-rex-grant-has-been-awarded-to-lift-biosciences-302271064.html SOURCE Bio-Techne Corporation | ||
Company Codes: NASDAQ-NMS:TECH |